Department of Nephrology, Centro Hospitalar do Médio Tejo, Hospital Rainha Santa Isabel, Torres Novas, Portugal.
Ther Apher Dial. 2022 Aug;26(4):790-796. doi: 10.1111/1744-9987.13766. Epub 2021 Dec 14.
Maintenance dialysis patients (MDP) are at higher risk of exposure with increased mortality from COVID-19 with generalized immunization becoming the cornerstone in prevention. This study aims to compare humoral response between hemodialysis (HD) and peritoneal dialysis (PD) patients.
Observational prospective study following HD and PD programs from a Portuguese Center receiving BNT162b2 vaccine. Specific anti-Spike IgG quantification to compare both for absolute value and non-responders (NR) between modalities and against risk factors.
Of 67 MDP, 42 were HD and 25 PD patients. PD developed higher antibody titers after both first (median 5.44 vs. 0.99 AU/ml, p < 0.01) and second dose (median 170.43 vs. 65.81 AU/ml; p < 0.01). HD associated with NR after the first dose (p < 0.01).
This study demonstrated improved humoral immunogenicity with BNT162b2 in PD compared to HD patients. These differences are attributed to comorbidity burden and age differences, rather than dialysis modality.
维持性透析患者（MDP）由于 COVID-19 导致的死亡率增加，面临更高的暴露风险，普遍免疫接种成为预防的基石。本研究旨在比较血液透析（HD）和腹膜透析（PD）患者的体液免疫反应。
这是一项观察性前瞻性研究，在葡萄牙的一个中心，对接受 BNT162b2 疫苗的 HD 和 PD 方案进行了随访。对特异性抗刺突 IgG 进行定量，比较两种模式之间的绝对值和无应答者（NR），并针对危险因素进行比较。
在 67 名 MDP 中，有 42 名 HD 患者和 25 名 PD 患者。PD 在接受第一剂（中位数 5.44 比 0.99 AU/ml，p<0.01）和第二剂（中位数 170.43 比 65.81 AU/ml；p<0.01）后产生了更高的抗体滴度。HD 与第一剂后 NR 相关（p<0.01）。
本研究表明，与 HD 患者相比，PD 患者使用 BNT162b2 后具有更好的体液免疫原性。这些差异归因于合并症负担和年龄差异，而不是透析模式。
